Notably, the combination of AB680, anti‐PD‐1 antibody, and CXCR2 inhibitor showed superior synergistic tumor suppression in vivo, providing an efficient and promising therapeutic strategy for PDAC. The gene discussed is CXCR2; the disease is neoplasm.